{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '23', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '- Objective: To compare overall survival (OS)', '- OS, defined as the time from', 'for the combinations of pembrolizumab +', 'randomization to death due to any cause*', 'lenvatinib versus pembrolizumab + matching', 'placebo.', '- Hypothesis (H2): The combination of', 'pembrolizumab + lenvatinib has superior os', 'Secondary Objectives', 'Secondary Endpoints', '- Objective: To compare objective response', '- Objective response (OR), defined as a', 'rate (ORR) as assessed by BICR according to', 'confirmed complete response (CR) or', 'RECIST 1.1, as defined in Section 4.2.1.1.1,', 'partial response (PR)', 'for the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab + matching', 'placebo', '- Hypothesis (H3): The combination of', 'pembrolizumab + lenvatinib has superior', 'ORR per RECIST 1.1, as defined in Section', '4.2.1.1.1, based on BICR', '- Objective: To evaluate the safety and', '- Adverse events (AEs) and study', 'tolerability for the combinations of', 'intervention discontinuation due to AEs', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Objective: To compare the mean change', '- Change from baseline for the following', 'from baseline in the global health', 'patient-reported outcomes (PROs)', 'status/quality of life (QoL), cough, chest pain,', 'scales/items: global health status/QoL', 'dyspnea, and physical functioning for the', '(EORTC QLQ-C30 items 29 and 30), cough', 'combinations of pembrolizumab + lenvatinib', '(EORTC QLQ-LC13 item 31), chest pain', 'versus pembrolizumab + matching placebo', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTC QLQ-C30 items 1-5)', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '24', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '- Objective: To compare the time to true', '- TTD, defined as the time from baseline to', 'deterioration (TTD) in global health', 'the first onset of a 10-point deterioration', 'status/QoL, cough, chest pain, dyspnea, and', 'from baseline with confirmation by the', 'physical functioning for the combinations of', 'subsequent visit of a 10-point deterioration', 'pembrolizumab + lenvatinib versus', 'from baseline in global health status/QoL', 'pembrolizumab + matching placebo', '(EORTC QLQ-C30 items 29 and 30), cough', '(EORTC QLQ-LC13 item 31), chest pain', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTC QLQ-C30 items 1-5)', '- TTD in the composite endpoint', '(combination of cough [QLQ-LC13 item', '31], chest pain [QLQ-LC13 item 40], or', 'dyspnea [QLQ-C30 item 8]) defined as the', 'time to first onset of a 10-point', 'deterioration from baseline in any one of 3', 'scale items with confirmation by the', 'subsequent visit of a 10-point deterioration', 'from baseline in the same scale as the first', 'onset', '*This study will be considered to have met its success criteria if the combination of', 'pembrolizumab + lenvatinib is superior to pembrolizumab + matching placebo in PFS or OS.', 'Overall Design:', 'Study Phase', 'Phase 3', 'Primary Purpose', 'Treatment', 'Indication', 'First-line treatment of metastatic NSCLC with PD-L1', 'expression (TPS 1%)', 'Population', 'Adult participants with treatment-na\u00efve, metastatic NSCLC', '(TPS 1%)', 'Study Type', 'Interventional', 'Intervention Model', 'Parallel', 'This is a multi-site study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}